Dianthus Therapeutics, Inc. to Post Q4 2024 Earnings of ($0.57) Per Share, HC Wainwright Forecasts (NASDAQ:DNTH)

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at HC Wainwright issued their Q4 2024 EPS estimates for shares of Dianthus Therapeutics in a research note issued on Thursday, May 16th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.57) for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.29) per share.

A number of other research analysts also recently commented on the company. Jefferies Financial Group upped their price objective on Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a "buy" rating in a research note on Friday, March 22nd. Wedbush increased their price objective on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the stock an "outperform" rating in a report on Friday, May 10th. Raymond James lifted their price objective on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the company an "outperform" rating in a research report on Thursday, April 18th. Finally, Stifel Nicolaus assumed coverage on shares of Dianthus Therapeutics in a research note on Thursday, February 15th. They issued a "buy" rating and a $44.00 price target on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Dianthus Therapeutics has a consensus rating of "Buy" and a consensus target price of $42.83.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock traded down $0.62 on Friday, reaching $25.63. 88,687 shares of the company were exchanged, compared to its average volume of 140,658. The firm has a market cap of $752.24 million, a price-to-earnings ratio of -4.40 and a beta of 1.77. Dianthus Therapeutics has a 1-year low of $6.58 and a 1-year high of $33.77. The company's 50-day moving average is $25.62 and its two-hundred day moving average is $18.78.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.11) by $0.40. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.73 million.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth approximately $25,000. Citigroup Inc. bought a new position in Dianthus Therapeutics during the 3rd quarter valued at $53,000. Hussman Strategic Advisors Inc. acquired a new position in shares of Dianthus Therapeutics during the 1st quarter valued at $630,000. Acadian Asset Management LLC bought a new stake in shares of Dianthus Therapeutics in the 3rd quarter worth $303,000. Finally, Laurion Capital Management LP acquired a new stake in shares of Dianthus Therapeutics in the third quarter valued at $497,000. Institutional investors and hedge funds own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.